Eli Lilly Obesity Pill Approval And Sleep Deal Reshape Growth Story [Yahoo! Finance]
Eli Lilly and Company (LLY)
Last eli lilly and company earnings: 4/23 06:25 am
Check Earnings Report
US:NYSE Investor Relations:
investor.lilly.com
Company Research
Source: Yahoo! Finance
Eli Lilly (NYSE:LLY) has received U.S. FDA approval for Foundayo, the first once daily oral GLP 1 pill for obesity, and has begun rapid U.S. commercialization. The company has reached a major U.S. government pricing and access agreement that broadens GLP 1 availability for Medicare and Medicaid patients. Eli Lilly is also acquiring Centessa Pharmaceuticals in a $7.8b deal to expand into sleep disorder treatments and broader neuroscience. Eli Lilly enters this series of updates with a market profile shaped by strong multi year returns, including a 27.7% gain over the past year and a 5 year increase of 433.0%. The current share price of $935.58 follows mixed shorter term moves, with the stock up 6.5% over the past week but showing a 5.5% decline over the past month and a 13.4% decline year to date. This backdrop provides context for assessing how the new GLP 1 pill, the government access deal, and the Centessa acquisition fit into the broader NYSE:LLY story. For investors, the
Show less
Read more
Impact Snapshot
Event Time:
LLY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LLY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LLY alerts
High impacting Eli Lilly and Company news events
Weekly update
A roundup of the hottest topics
LLY
News
- 25th Annual Bio-IT World Conference & Expo in Boston Leads the Conversation on Operationalizing AI Across Real-World Drug Discovery Environments [Yahoo! Finance]Yahoo! Finance
- Eli Lilly and Company (LLY) was downgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=LLY&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "stMarketBeat
- Jim Cramer Believes Eli Lilly's “Weight Loss Pill Will Be a Blockbuster” [Yahoo! Finance]Yahoo! Finance
- Eli Lilly's One-Two Punch Could Knock Novo Nordisk Out of the Obesity Drug Fight [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- Jim Cramer Likes Eli Lilly's (LLY) New Deal [Yahoo! Finance]Yahoo! Finance
LLY
Earnings
- 2/4/26 - Beat
LLY
Sec Filings
- 3/26/26 - Form SCHEDULE
- 3/20/26 - Form DEFA14A
- 3/20/26 - Form DEF
- LLY's page on the SEC website